Optimization of the supplemental essential amino acids to a fish meal-free diet based on fermented soybean meal for rainbow trout <Emphasis Type="Italic">Oncorhynchus mykiss</Emphasis>

To minimize the supplemental essential amino acids (EAAs) to a fish meal-free diet for rainbow trout Oncorhynchus mykiss, four types of fish meal-free diets and a control fish meal-based diet were fed to triplicate groups of trout (initial BW, 16 g) for 10 weeks. Two fish meal-free diets based on a fermented and an unfermented soybean meal were unsupplemented with EAAs (diet FSBM and SBM), and two fish meal-free diets based on the fermented soybean meal were supplemented with a combination of lysine and methionine (diet F + ML) and all EAAs (diet F + All), the EAA contents of which were lower than those of the control diet (diet FM). Although physiological conditions such as the biliary bile acid status and morphological features of fish fed diet FSBM were improved and similar to those of fish fed diet FM, the growth performance was not significantly different (P > 0.05) from fish fed diet SBM. The growth performances and whole body protein contents of fish fed F + ML and F + All diets were similarly improved compared to fish fed diet FSBM. These findings indicate that supplementation of lysine and methionine to a fermented soybean meal-based fish meal-free diet is enough to maximize the amino acid utilization of the diet.     

Prognosis of canine patients with nasal tumors according to modified clinical stages based on computed tomography: a retrospective study

To evaluate the efficacy of clinical staging based on computed tomography (CT) imaging over the World Health Organization (WHO) staging system based on radiography for nasal tumors in dogs, a retrospective study was conducted. This study used 112 dogs that had nasal tumors; they had undergone radiography and CT and had been histologically confirmed as having nasal tumors. Among 112 dogs, 85 (75.9%) were diagnosed as adenocarcinoma. Then they were analyzed for survival time according to each staging system. More than 70% of the patients with adenocarcinoma were classified as having WHO stage III. The patients classified under WHO stage II tended to survive longer than those classified under WHO stage III. Dogs classified under WHO stage III were further grouped into CT stages III and IV, and CT stage III patients had a significantly longer survival time than CT stage IV patients. In addition, patients treated with a combination of surgery and radiation had a significantly longer survival time than the patients who did not receive any treatment in CT stage III. On the other hand, different treatment modalities did not show a significant difference in the survival time of CT stage IV dogs. The results suggest that WHO stage III dogs may have various levels of tumor progression, indicating that the CT staging system may be more accurate than the WHO staging system.